Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

IB-367: IntraBiotic's first drug candidate

July 12, 1996

Multidrug resistance modifiers from Vertex

July 12, 1996

Interim phase I/IIa results for Genta's G-3139 as non-Hodgkin's lymphoma agent

July 12, 1996

Canji issued two patents for p53 gene therapy for cancer

July 12, 1996

Arizona Board of Regents reports antitumor pentapeptides

July 12, 1996

Potent tyrosine kinase inhibitors derived from PD-089828

July 12, 1996

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

July 12, 1996

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

July 12, 1996

Protein tyrosine kinase inhibitors from Warner-Lambert

July 12, 1996

Arimidex approved for Austrian, German and Italian markets

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...